Back

Bleeding risk for non-valvular AF patients prescribed warfarin, or standard doses of apixaban 5mg BID, dabigatran 150mg BID or rivaroxaban 20mg QD in real-world practice: Findings from EHR

28 August 2016 (14:18 - 14:36)
Organised by:
Congress Presentation Part of: Are you still afraid about bleeding risk of antithrombotic therapy in atrial fibrillation? Atrial fibrillation (AF) ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Gregory Yh Lip

University of Liverpool, Liverpool (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
State of the art in bleeding risk in atrial fibrillation.
Professor I. Van Gelder (Groningen, NL)
Slides Video
Presentation thumbnail
Factors associated with quality of anticoagulation control in patients with atrial fibrillation and risk of stroke and bleeding
Mr A. Nissen Bonde (Roskilde, DK)
Abstract Slides Video
Presentation thumbnail
Major bleeding among patients with atrial fibrillation treated with rivaroxaban or warfarin in Sweden. Interim results from an on-going post-authorization study
Associate Professor L. Friberg (Bromma, SE)
Abstract Slides Video
Presentation thumbnail
Future direction for research in antithrombotic therapy in atrial fibrillation.
Professor E. Hylek (Boston, US)
Slides Video

Access the full session

Session thumbnail
Are you still afraid about bleeding risk of antithrombotic therapy in atrial fibrillation?

The Event

Event poster

ESC Congress 2016

28 August 2016 14:18 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources